Selegiline Reference

Plain English

What it is

Selegiline is an FDA-approved prescription medicine sold under brand names like Eldepryl, Zelapar, and Emsam. It is a type of MAO-B inhibitor, which changes how the brain breaks down certain chemical messengers.

What people use it for

By mouth (Eldepryl, Zelapar) it is approved to help treat Parkinson's disease, and as a skin patch (Emsam) it is approved for major depression. Outside of those approved uses, some people in the nootropic and longevity community use very small amounts hoping for sharper thinking or anti-aging effects, but that is off-label, meaning it is not what the FDA cleared the drug for.

What the science shows

The evidence for its approved Parkinson's and depression uses was strong enough to earn FDA approval. The research behind the off-label brain-boosting and longevity claims is older and based on small studies, so those benefits remain largely unproven.

The catch

Selegiline can trigger serotonin syndrome, a dangerous and possibly life-threatening reaction, if combined with antidepressants or other drugs that raise serotonin (such as SSRIs, SNRIs, tramadol, or dextromethorphan). At higher amounts it can also lose its selectivity and react with tyramine in aged foods (aged cheeses, cured meats), which can cause a sudden, possibly fatal spike in blood pressure. It is prescription-only and meant to be used under a doctor's care.

Reference summary

Selegiline is label-verified for Parkinson's and MDD. Off-label longevity / cognitive use literature is older (Knoll et al.) and small.

Regulatory and posture

Categories

Nootropic, Cognitive

Aliases

Deprenyl, L-Deprenyl, Eldepryl, Emsam, Zelapar

Evidence posture

human - FDA-approved for Parkinson's disease and MDD. Off-label nootropic / longevity micro-dosing is outside the FDA label. MAO-B inhibition becomes non-selective at higher doses; tyramine-containing foods (aged cheeses, cured meats) can produce hypertensive crises at non-selective doses. Concomitant SSRIs / serotonergic agents can produce serotonin syndrome.

Regulatory status

FDA-approved prescription medication. Eldepryl / Zelapar are oral selegiline approved as adjunctive Parkinson's disease therapy. Emsam is a transdermal selegiline approved for major depressive disorder. Off-label nootropic micro-dosing is outside the FDA label and may interact dangerously with tyramine-containing foods (Emsam transdermal at higher doses requires dietary restriction) and serotonergic agents.

Content review status

label verified